Brief: Immuneonco Biopharmaceuticals Shanghai Inc Recives Approval By NMPA For Clinical Trial Of Imc-003/Imm72
23/06/2025 02:39
June 23 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK: APPROVAL BY NMPA FOR CLINICAL TRIAL OF IMC-003/IMM72 Further company coverage: 1541.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S